Skip to main content

Table 5 Summary of best spleen response and symptom score change from baseline in phase 2 (efficacy evaluable population)a

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Endpoint Patients achieving endpoint, n/N (%)
95% CI
At week 24 visit Up to week 24 visit At end of treatment Up to end of treatment
≥35% spleen volume reduction by MRI 4/17 (23.5) 5/23 (21.7) 4/23 (17.4) 7/23 (30.4)
95% CI 6.8–49.9 95% CI 5.0–38.8
≥50% spleen length reduction by physical examination 9/19 (47.4) 12/31 (38.7) 9/31 (29.0) 12/31 (38.7)
95% CI 24.4–71.1 95% CI 14.2–48.0
≥50% reduction in MF Quality of Life and Symptom Assessment total symptom score 7/18 (38.9) 12/29 (41.4) 4/29 (13.8) 12/29 (41.4)
  1. aPatients included in the efficacy evaluable population are those who had both a non-missing baseline measurement and post-baseline measurement at or through the time point specified
  2. MRI magnetic resonance imaging